BioPharma Resources

Drug Trial Radar · NCT07308236

A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants

An Open-Label, Single Dose Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Subjects

Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Dec 31, 2025

Primary completion

Jun 12, 2026

Study completion Jun 12, 2026

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Dec 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to determine the metabolism and excretion of \[14C\]E2086 in healthy male participants.

Conditions

  • Healthy Volunteers

Interventions

  • E2086Drug

    E2086 oral capsule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mass Balance Recovery of E2086, Expressed as Cumulative Percent of the Radiolabeled DoseTime frame: Day 1 up to Day 21
  2. Maximum Observed Concentration (Cmax) of [14C]E2086 for Total Radioactivity (TRA) in PlasmaTime frame: Day 1 up to Day 21
  3. Time to Reach Cmax (Tmax) of [14C]E2086 for TRA in PlasmaTime frame: Day 1 up to Day 21
  4. Area Under the Concentration-time Curve from Zero Time to Time of Last Quantifiable Concentration [AUC (0-t)] of [14C]E2086 for TRA in PlasmaTime frame: Day 1 up to Day 21
  5. Area Under the Concentration-time Curve from Zero Time Extrapolated to Infinite Time [AUC (0-inf)] of [14C]E2086 for TRA in PlasmaTime frame: Day 1 up to Day 21
  6. Terminal Elimination Phase Half-life (t1/2) of [14C]E2086 for TRA in PlasmaTime frame: Day 1 up to Day 21
  7. Cmax of [14C]E2086 for TRA in Whole BloodTime frame: Day 1 up to Day 21
  8. Tmax of [14C]E2086 for TRA in Whole BloodTime frame: Day 1 up to Day 21
  9. AUC (0-t) of [14C]E2086 for TRA in Whole BloodTime frame: Day 1 up to Day 21
  10. AUC (0-inf) of [14C]E2086 for TRA in Whole BloodTime frame: Day 1 up to Day 21
  11. t1/2 of [14C]E2086 for TRA in Whole BloodTime frame: Day 1 up to Day 21
  12. Cmax of E2086 and its Metabolite M1 in Plasma Using liquid Chromatography Coupled With Mass Spectrometry (LC-MS/MS)Time frame: Day 1 up to Day 21
  13. Tmax E2086 and its Metabolite M1 in Plasma Using LC-MS/MSTime frame: Day 1 up to Day 21
  14. AUC (0-t) of E2086 and its Metabolite M1 in Plasma Using LC-MS/MSTime frame: Day 1 up to Day 21
  15. AUC (0-inf) of E2086 and its Metabolite M1 in Plasma Using LC-MS/MSTime frame: Day 1 up to Day 21
  16. t1/2 of E2086 and its Metabolite M1 in Plasma Using LC-MS/MSTime frame: Day 1 up to Day 21
  17. Apparent Total Clearance (CL/F) of E2086 in Plasma Using LC-MS/MSTime frame: Day 1 up to Day 21
  18. Apparent Volume of Distribution (Vz/F) at Terminal Phase of E2086 in Plasma Using LC-MS/MSTime frame: Day 1 up to Day 21
  19. Metabolite Ratio (MRp) of E2086 and its Metabolite M1 in Plasma Using LC-MS/MSTime frame: Day 1 up to Day 21
  20. Cumulative Amount Excreted in Urine from Zero Time to Time of Last Interval (Ae) of E2086 and its Metabolite M1 in Urine Using LC-MS/MSTime frame: Day 1 up to Day 21
  21. Fraction of Dose Excreted in Urine from Zero Time to Time of Last Interval (Fe) of E2086 and its Metabolite M1 in Urine Using LC-MS/MSTime frame: Day 1 up to Day 21
  22. Renal Clearance (CLR) of E2086 and its Metabolite M1 in Urine Using LC-MS/MSTime frame: Day 1 up to Day 21
  23. MRu of E2086 and its Metabolite M1 in Urine Using LC-MS/MSTime frame: Day 1 up to Day 21
  24. Percentage of Administered Radioactive Dose Excreted in Urine, Feces, and Toilet Tissue by TRATime frame: Day 1 up to Day 21

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fortrea Clinical Research Unit Inc.

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.